Known targets — ChEMBL curated mechanism
ACHEADRA1AADRA1BADRA1DADRA2AADRA2BADRA2CADRB1ADRB2ADRB3APH1AAPH1BCHRM2CHRM3EZH2GRIN2AHTR1AHTR1BHTR1DHTR1FHTR3ANCSTNP2RY12PSEN1PSEN2PSENENSIGMAR1SLC6A2SLC6A3SLC6A4
The experimentally established mechanism targets of Bromide. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR1A known ✓ | P08908 | 1/20 | 0.33 |
| ▸ | ADRA2A known ✓ | P08913 | 1/20 | 0.33 |
| ▸ | ADRA2B known ✓ | P18089 | 1/20 | 0.33 |
| ▸ | ADRA2C known ✓ | P18825 | 1/20 | 0.33 |
| ▸ | SLC6A2 known ✓ | P23975 | 1/20 | 0.33 |
| ▸ | ADRA1A known ✓ | P35348 | 1/20 | 0.33 |
| ▸ | SLC6A3 known ✓ | Q01959 | 1/20 | 0.33 |
| ▸ | HIF1A | Q16665 | 5/20 | 0.47 |
| ▸ | CYP2C9 | P11712 | 3/20 | 0.47 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.47 |
| ▸ | HSD17B10 | Q99714 | 6/20 | 0.42 |
| ▸ | CYP3A4 | P08684 | 5/20 | 0.42 |
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.42 |
| ▸ | TSHR | P16473 | 4/20 | 0.42 |
| ▸ | RECQL | P46063 | 2/20 | 0.42 |
| ▸ | HPGD | P15428 | 6/20 | 0.41 |
| ▸ | GABRA1 | P14867 | 1/20 | 0.39 |
| ▸ | GABRB1 | P18505 | 1/20 | 0.39 |
| ▸ | HSP90AA1 | P07900 | 2/20 | 0.38 |
| ▸ | MEN1 | O00255 | 4/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Bromide SCHEMBL6440480 | 1.00 | HIF1A (0.47) | HIF1ACYP2C9CYP2C19HSD17B10CYP3A4 | |
| SCHEMBL29516784 | 0.97 | HIF1A (0.48) | HIF1ACYP2C9CYP2C19HSD17B10CYP3A4 | |
| SCHEMBL9993152 | 0.86 | HSD17B10 (0.56) | HIF1ACYP2C9CYP2C19HSD17B10CYP3A4 | |
| SCHEMBL11591823 | 0.84 | ERN1 (0.47) | HIF1ACYP2C9CYP2C19HSD17B10CYP3A4 | |
| SCHEMBL29087535 | 0.78 | HSPA5 (0.46) | HIF1ACYP2C9CYP2C19HSD17B10CYP3A4 | |
| SCHEMBL21437010 | 0.76 | BACE1 (0.39) | ALDH1A1GABRA1ESR1ESR2 | |
| SCHEMBL1004123 | 0.74 | CYP2C9 (0.50) | HIF1ACYP2C9CYP2C19HSD17B10CYP3A4 | |
| SCHEMBL22543122 | 0.74 | TRPA1 (0.33) | CYP2C9HSD17B10ALDH1A1TSHRGABRA1 | |
| SCHEMBL11336884 | 0.74 | HIF1A (0.50) | HIF1ACYP2C9CYP2C19HSD17B10CYP3A4 | |
| SCHEMBL6443715 | 0.72 | AMY1A (0.48) | HIF1ACYP2C9CYP2C19HSD17B10ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6919456-B2 | Catalytic compositions and methods for asymmetric aldol reactions | THE BOARD OF TRUSTEES OF THE LELAND STANFORD JUNIOR UNIVERSITY (US) | 2005-07-19 | — | — | US | disclosed |
| EP-1409122-A2 | CATALYTIC COMPOSITIONS AND METHODS FOR ASYMMETRIC ALDOL REACTIONS | THE BOARD OF TRUSTEES OF THE LELAND STANFORD JUNIOR UNIVERSITY (US) | 2004-04-21 | — | — | EP | disclosed |
| US-20040019239-A1 | Catalytic compositions and methods for asymmetric aldol reactions | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2004-01-29 | — | — | US | disclosed |
| US-6610889-B2 | Using organometallic complex catalyst | THE BOARD OF TRUSTEES OF THE LELAND STANFORD JUNIOR UNIVERSITY | 2003-08-26 | — | — | US | disclosed |
| US-20020147367-A1 | Catalytic compositions and methods for asymmetric aldol reactions | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2002-10-10 | — | — | US | disclosed |
| WO-2002041984-A2 | CATALYTIC COMPOSITIONS AND METHODS FOR ASYMMETRIC ALDOL REACTIONS | THE BOARD OF TRUSTEES OF THE LELAND STANFORD JUNIOR UNIVERSITY (US) | 2002-05-30 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020147367-A1 | Catalytic compositions and methods for asymmetric aldol reactions | ADH1C, ADH5, ADH1A | HTR1A 3763/4885ADRA2A 739/4885ADRA2B 637/4885 |
| US-20040019239-A1 | Catalytic compositions and methods for asymmetric aldol reactions | ADH1C, ADH5, ADH1A | HTR1A 3763/4885ADRA2A 739/4885ADRA2B 637/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.